CordenPharma completes early development suite at Plankstadt facility

By Melissa Fassbender

- Last updated on GMT

(Image: iStock/Golden_Brown)
(Image: iStock/Golden_Brown)

Related tags Completeness

CordenPharma has completed development of an early development suite for highly potent, oral solid dosage products at its Plankstadt, Germany location.

According to the contract manufacturing organization (CMO), the new facility enables the production of small batches from 100g to approximately 1,000g. The facility is able to provide compounds with various potencies and containment degrees.

"The setup in the new facility of CordenPharma Plankstadt is very flexible – it allows for operations to take place at three different levels of containment​," said Jason Bertola, director, global highly potent and oncology platform, CordenPharma International.

"Basically, it progresses from an open system for non-highly potent ​compounds, to a semi-closed system (sliding glass pane) to a fully enclosed system for OEL below 1mg/m3. The containment systems can be connected by Rapid Transfer Port (RTP) to allow the transfer in and out of the individual barriers safely​," he told us. 

As Bertola explained, the production of small technical batches was a gap in CordenPharma's service offering and the new facility addresses this gap. "This area is non-GMP and designed for development work​," he added.

The addition follows a series of investments made during the past year, including expanded capacity and capabilities at its Boulder, Colorado facility in the US.

The company has also recently implemented​ a program to address corporate and quality systems, organization structure and infrastructure, and includes a process to involve customers in improving transparency. 

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Pulmonary Delivery of Orally Inhaled Therapeutics

Pulmonary Delivery of Orally Inhaled Therapeutics

Content provided by Catalent Pharma Solutions | 19-Oct-2023 | Business Advice

New classes and indications of orally inhaled therapeutics are rapidly expanding, with the development pipeline increasingly featuring both large and small...

Addressing Challenges with Clinical In-Use Testing

Addressing Challenges with Clinical In-Use Testing

Content provided by Lonza | 12-Oct-2023 | White Paper

Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...

Related suppliers

Follow us


View more